UNSPSC 51341504: Fosfonet

This classification denotes a reverse transcriptase inhibitor and antiviral agent with the molecular formula C2H5O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N919E46723, chemically known as phosphonoacetic acid, disodium salt, monohydrate but generally known as fosfonet, which bears US NIH Compound Identifier 546. World Health Organization schedules fosfonet in its Anatomical Therapeutic Chemical (ATC) Classification.

FOSFONET is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C(C(=O)O)P(=O)(O)O.

UNSPSC 51341504 Fosfonet, a Commodity code, reflects state and local government procurement of naloxone and pharmaceutical deactivation systems, along with broader pharmacy benefit management services and pharmaceutical products. Recent opportunities under this code show purchasing bodies acquiring naloxone supplies for emergency response and community health, managing prescription fulfillment through direct-to-manufacturer arrangements, and sourcing generic pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The scope encompasses both high-volume consumable pharmaceuticals and specialized emergency medical supplies, with issuing bodies ranging from county health departments to state health and human services agencies and municipal fire departments.

Activity spans Florida, Texas, and Minnesota, with Seminole County, Florida procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS (response deadline July 26, 2023); the Texas Health and Human Services Commission issuing RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; the City of Tampa's Fire Department soliciting medical and first aid supplies including respiratory equipment and cardiac monitoring devices through ITB 26P00145 (due March 13, 2026) with an estimated contract value of $700,000 and a 5% small local business enterprise discount available; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through authorized wholesalers, with products required available by May 15, 2026 and contracts effective July 1, 2026. The cooperative purchasing vehicle and multi-state participation in the MMCAP procurement suggest regional consolidation of pharmaceutical sourcing among state and local health systems.